• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Novo Nordisk A/S Common Stock (NY: NVO )

    87.89 +0.52 (+0.60%)
    Streaming Delayed Price Updated: 2:21 PM EST, Dec 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Novo Nordisk A/S Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    68 69 Next >
    Musk Tests Mounjaro, Ozempic, Wegovy: Which Weight-Loss Drug Won Him Over?
    Elon Musk sparked conversation about weight-loss drugs and side effects with a Christmas social media post. 
    Via Benzinga
    Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear.
    Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for investors. 
    Via The Motley Fool
    Down 19% in 1 Day, Is Novo Nordisk Stock Still a Buy?
    Via The Motley Fool
    Tech Stocks Eye Christmas Gains, Microstrategy Tumbles As Bitcoin Dips To $93,000: What's Driving Markets Monday?
    Tech stocks began Christmas week with positive momentum, as the Nasdaq 100 rose 0.4% on Monday, building on a 0.7% gain from Friday. The index has now recovered nearly half of the losses sustained... 
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    What Analysts Are Saying About Novo Nordisk Stock
    Via Benzinga
    $100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
    Via Benzinga
    Better Buy: Eli Lilly or Novo Nordisk?
    Novo Nordisk stock crashed 17% on Friday after revealing disappointing trial results. 
    Via The Motley Fool
    Novo Nordisk Rises 5% In Premarket As Analyst Dismisses Friday's 17% Plunge As Market Overreaction
    Analysts at Intron Health, led by Naresh Chouhan, suggested that Friday's market reaction was excessively severe. 
    Via Benzinga
    Novo Nordisk, Super Micro Computer And Arm Are Among Top Large Cap Losers Last Week (December 16-20): Are The Others In Your Portfolio?
    11 worst-performing large-cap stocks: NVO, VRTX, XPO, SMCI, NU, ARM, MU, PAYC, CTAS, WBD, MNDY. Blame fiscal spending package, Fed rate hike, weak earnings. 
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Is Merck the Next Big Weight-Loss Stock?
    Via The Motley Fool
    Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug
    The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans. 
    Via Benzinga
    Exposures Product Safety
    MarketBeat Week in Review – 12/16 - 12/20
    Stocks were lower this week after the Federal Reserve confirmed fewer rate cuts in 2025, but Friday's rally suggests hope for a Santa Claus rally remains strong 
    Via MarketBeat
    Topics Artificial Intelligence Economy
    Exposures Artificial Intelligence Interest Rates
    3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
    Via The Motley Fool
    Is Now a Good Time to Buy the Dip in Eli Lilly Stock?
    Since Eli Lilly reported third-quarter earnings on Oct. 30, its shares have had a prolonged sell-off. 
    Via The Motley Fool
    Why Viking Therapeutics Tumbled by More Than 10% This Week
    Via The Motley Fool
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Dow Surges Over 600 Points, Gold Jumps 1.5%
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Wall Street Rallies On Soft Inflation Data, Bonds Rebound, Travel Stocks Surge: What's Driving Markets Friday?
    Risk sentiment returned to Wall Street on Friday, revitalized by softer-than-expected November inflation data leading to a strong market rebound following the selloff triggered by the Federal Reserve’s... 
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    What's Going On With Amgen Stock On Friday?
    Novo Nordisk's CagriSema shows 22.7% weight loss in Phase 3 trials, while tolerability concerns grow. MariTide offers competitive weight loss with less frequent dosing. 
    Via Benzinga
    Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher
    Via Benzinga
    Novo Nordisk Stock Plummets: Bearish Signals Dominate After Drug Trial Miss
    Novo Nordisk's stock is spiraling downwards, with technical analysis revealing a concerning picture of bearish momentum. Short-term opportunities may arise, but the broader downtrend remains strong. 
    Via Benzinga
    Dow Up 752 Points, Extending Rebound From Dramatic Losses
    The Dow Jones Industrial Average is in rally mode, reversing its premarket losses to jump 752 points after yesterday snapping its 10-day losing streak. 
    Via Talk Markets
    Topics Stocks Stocks / Equities
    Exposures US Equities
    Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up
    Today's sell-off in Novo Nordisk may be the buying opportunity you've been waiting for. 
    Via The Motley Fool
    Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook: Weekly Review
    Micron, Vertex, Novo Nordisk and Nike were notable losers on news. 
    Via Investor's Business Daily
    Topics Economy
    Exposures Interest Rates
    EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss
    Novo Nordisk's stock plunges 20% after underwhelming weight-loss trial results for its obesity drug. Analysts say market overreacted. 
    Via Benzinga
    US Steel Issues Weak Q4 Outlook, Joins Novo Nordisk And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    Via Benzinga
    Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump.
    Eli Lilly and Viking Therapeutics jumped on Novo's setback. 
    Via Investor's Business Daily
    Novo Nordisk's Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges
    Novo Nordisk's REDEFINE 1 trial shows CagriSema delivers significant weight loss and a favorable safety profile in obesity treatment. 
    Via Benzinga
    Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Elon Musk Vs. RFK Jr.: Obesity Crisis Debate Sparks Struggle For Trump's Influence
    Debate over tackling U.S. obesity epidemic sparks contrasting views from Trump's orbit: lifestyle changes vs. easier access to weight-loss drugs. 
    Via Benzinga
    Topics Government
    Exposures Political
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    68 69 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.